On October 9, 2017 Athersys, Inc. (Nasdaq:ATHX) reported that it will release its third quarter 2017 financial results at approximately 4:00 PM Eastern Time on Wednesday, November 8, 2017, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results (Press release, Athersys, OCT 9, 2017, View Source [SID1234520902]). Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:

Date November 8, 2017
Time 4:30 p.m. (Eastern Time)
Telephone access: US and Canada (800) 273-1254
Telephone access: International (973) 638-3440
Access code 96178367
Live webcast www.athersys.com under Investors section

A replay will be available for on-demand listening shortly after the completion of the call until 11:59 PM Eastern Time on November 22, 2017 at the aforementioned URL, or by dialing (800) 585-8367 or (855) 859-2056 in the U.S. and Canada, or from abroad (404) 537-3406, and entering access code 96178367.

On October 9, 2017 AbbVie (NYSE: ABBV) reported that it will announce its third-quarter 2017 financial results on Friday, Oct. 27, 2017, before the market opens (Press release, AbbVie, OCT 9, 2017, View Source [SID1234520903]).

AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time (9 am Eastern). It will be accessible through AbbVie’s Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

On October 09, 2017 Radius Health (Nasdaq:RDUS) reported that it will release its third quarter 2017 financial results on Thursday, November 2, 2017 (Press release, Radius, OCT 9, 2017, View Source [SID1234520904]). The Company will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the results and provide a company update.

Conference Call Information:
Date: Thursday, November 2, 2017
Time: 4:30 p.m. ET
Domestic Dial-in Number: (866) 323-7965
International Dial-in Number: (346) 406-0961
Conference ID: 96777747
Live webcast: View Source

A replay of the conference call/webcast will be available from November 2, 2017 at 7:30 p.m. ET until November 9, 2017 at 6:30 p.m. ET. To access the replay, dial (855) 859-2056 for U.S. or (404) 537-3406 for International. The replay conference ID is 96777747.

The live audio webcast of the call can be accessed from the Investors section of the Company’s website, www.radiuspharm.com. A webcast replay will be also available for 14 days. The full text of the announcement and financial results will also be available on the Company’s website.

On October 9, 2017 Endo International plc (NASDAQ: ENDP) reported that it will announce its third-quarter 2017 financial results on November 9, 2017 and members of its senior management team will host a conference call and webcast after the U.S. financial markets close at 4:30 p.m. ET (Press release, Endo Health Solutions, OCT 9, 2017, View Source [SID1234520905]).

The dial-in number to access the call is U.S./Canada (866) 497-0462, International (678) 509-7598, and the passcode is 92375212. Please dial in 10 minutes prior to the scheduled start time.

A replay of the call will be available from November 9, 2017 at 7:30 p.m. ET until 7:30 p.m. ET on November 23, 2017 by dialing U.S./Canada (855) 859-2056, International (404) 537-3406, and entering the passcode 92375212.
A simultaneous webcast of the call can be accessed by visiting www.endo.com. In addition, a replay of the webcast will be available until 7:30 p.m. ET on November 23, 2017. The replay can be accessed by clicking the Investor Relations section of the website.

On October 9, 2017 NanOlogy LLC , a clinical-stage pharmaceutical development company, reported enrollment of the first patient in a Phase 2 clinical trial of intraperitoneally (IP) administered NanoPac (nanoparticle paclitaxel) sterile suspension in patients with ovarian cancer (Press release, NanOlogy, OCT 9, 2017, View Source [SID1234520817]). Part of a broad nanoparticle technology platform developed by the company, NanoPac will be evaluated for safety and efficacy after IP instillation of NanoPac at the end of cytoreductive (debulking) surgery.

“Systemically administered paclitaxel has been shown to be effective in ovarian cancer but is limited by its adverse effects,” said Gere diZerega, MD, VP of Medical Affairs. “We are attempting to show that a single, IP-instilled dose of NanoPac will effectively treat the cancer with high locally sustained concentrations of the drug and no contribution to systemic adverse effects.”

Ovarian cancer is newly diagnosed in more than 22,000 women annually and almost 70% of these women will die from the disease. As a result, ovarian cancer is the fifth leading cause of cancer-related deaths in women. First line treatment is surgery to remove as much of the tumor as possible followed by systemic chemotherapy to attempt to eradicate any of the cancer that remains.

“If successful, we may add to the newer treatment options that are just becoming available and ideally improve the prognosis and quality of life for patients diagnosed with ovarian cancer,” said Marc Iacobucci of NanOlogy.

NanOlogy has an extensive clinical development program underway for NanoPac sterile suspension, including clinical trials in ovarian cancer (with orphan drug designation), prostate cancer, pancreatic cancer, and pancreatic mucinous cysts. In addition, NanOlogy and affiliate, DFB Soria, are progressing clinical trials for Soria-developed SOR007 (nanoparticle paclitaxel) ointment in cutaneous metastases and actinic keratosis. Clinical trials for NanoDoce (nanoparticle docetaxel) are planned in 2018 pending IND approval. An inhaled version of NanoPac is in a preclinical efficacy study for lung cancer after pharmacokinetic studies demonstrated retention of drug in lung tissues for more than 14 days following nebulized delivery and no abnormalities within the trachea or lung upon gross and histologic exam.

The NanOlogy nanoparticle technology platform is based on a patented production process that reduces the size of paclitaxel and docetaxel API crystals by up to 400 times into patented, stable, naked nanoparticles with exponentially increased surface area and unique geometry. Unlike other nanoparticles, which use coating agents for stability, NanoPac and NanoDoce are stable in their naked form and suspended prior to use in simple vehicles without coating agents.